Sanofi Consumer Healthcare India Ltd (SANOFICONR)
₹4,674.70
Mkt cap
₹10,431 Cr
P/E ratio
41.20
P/B
27.99
Div yield
1.66%
ROE
71.60%
ROCE
89.90%
EPS (TTM)
₹113.46
Book value
₹167
52W range
4,000–5,367
Sector
Healthcare
Incorporated in 2023, Sanofi Consumer Healthcare India Ltd manufactures and trading of drugs & pharmaceutical products. [1] It is a division of Sanofi, a global pharmaceutical company, focusing on over-the-counter (OTC) and consumer healthcare products. [2]
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−12.89% from high₹4,675
₹4,000+16.88% from low₹5,367
Current
₹4,674.70
Prev close
₹4,650.00
Day
+0.53%
Price performance
1D
+0.53%
1W
+3.22%
1M
+1.23%
3M
+1.73%
6M
+15.26%
1Y
−8.83%
YTD
+1.72%
Financials
FRevenue, profit & margin
P/E ratio
41.2×
SANOFICONR is 18% above the sector median of 34.9×
SANOFICONR41.2×
Sector median34.9×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 210 | 225 | 222 | 172 | 160 | 171 | 173 | 221 | 234 | 251 | 229 | |
| Expenses | 116 | 135 | 140 | 109 | 97 | 109 | 109 | 151 | 149 | 161 | 140 | |
| Operating Profit | 95 | 90 | 82 | 64 | 63 | 62 | 64 | 70 | 85 | 90 | 89 | |
| OPM % | 45% | 40% | 37% | 37% | 39% | 36% | 37% | 32% | 36% | 36% | 39% | |
| Other Income | 1 | 1 | 3 | -24 | 3 | 2 | 5 | 12 | 3 | 5 | 6 | |
| Interest | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 | 3 | 3 | |
| Profit before tax | 95 | 90 | 84 | 39 | 61 | 63 | 67 | 79 | 84 | 90 | 91 | |
| Tax % | 25% | 24% | 25% | 25% | 26% | 29% | 25% | 23% | 25% | 27% | 25% | |
| Net Profit | 71 | 68 | 63 | 29 | 45 | 44 | 50 | 61 | 63 | 66 | 68 | |
| EPS in Rs | 12.59 | 19.54 | 19.24 | 21.71 | 26.36 | 27.31 | 28.87 | 29.44 | ||||
| Raw PDF |
Earnings
EResults dates & reactionsNext results
28 Jul '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Mar 202671.27%Promoter
Promoters71.27%
FIIs2.76%0.07
DIIs17.57%0.24
Public8.41%0.16
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,951.50 | 37.68 | 4,68,230 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,273.00 | 73.61 | 1,93,075 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.96% |
| Torrent Pharma. | ₹5,017.80 | 77.49 | 1,69,825 | 0.76% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,438.00 | 30.52 | 1,16,168 | 0.90% | 543 | −54.61% | 6,541 | −2.80% | 15.49% |
| Zydus Lifesci. | ₹1,156.90 | 21.27 | 1,15,401 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,493.00 | 20.05 | 1,13,988 | 0.72% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,543.10 | 52.29 | 1,05,054 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.50% |
| Sanofi Consumer | ₹4,523.60 | 41.25 | 10,431 | 1.66% | 68 | +35.60% | 229 | +32.79% | 89.93% |
| Median: 156 Co. | ₹434.68 | 34.87 | 2,006 | 0.08% | 12 | +22.43% | 177 | +16.46% | 15.19% |
Filings
DAnnual reports2
Concall transcripts2
Announcements5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Jul - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 3oth June 2026 is enclosed.Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s 29 Jun - Shareholders approved PwC as statutory auditor25 May 2026 through 8th AGM in 2031.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 29 JunShareholder Meeting / Postal Ballot-Outcome of AGM 26 JunClosure of Trading Window 26 Jun - Trading window closed1 July 2026 until 48 hours after Q1FY27 results.